

Supplemental Information

**Cytokine and chemokine signatures associated  
with hepatitis B surface antigen loss  
in hepatitis B patients**

Sachiyo Yoshio<sup>1</sup>, Yohei Mano<sup>1</sup>, Hiroyoshi Doi<sup>1</sup>, Hirotaka Shoji<sup>1</sup>, Tomonari Shimagaki<sup>1</sup>,


Yuzuru Sakamoto<sup>1</sup>, Hironari Kawai<sup>1</sup>, Michitaka Matsuda<sup>1</sup>, Taizo Mori<sup>1</sup>, Yosuke

Osawa<sup>1</sup>, Masaaki Korenaga<sup>1</sup>, Masaya Sugiyama<sup>2</sup>, Masashi Mizokami<sup>2</sup>, Eiji Mita<sup>3</sup>,

Keiko Katayama<sup>4</sup>, Junko Tanaka<sup>4</sup> and Tatsuya Kanto<sup>1\*</sup>


**Figure S1**

**Serum CXCL9, CXCL10, CXCL11, CXCL13 and IL-21 levels for each viral genotype in the patients with acute HBV infection.** Serum CXCL9, CXCL10, CXCL11, CXCL13, and IL-21 levels for AH patients (including the sAH and pAH groups) were compared among genotype A(n=21), B(n=7), and C (n=21). Samples obtained at the peak of alanine aminotransferase (ALT) elevation were subjected to analyses. Box and whisker plots show median, lower and upper quartiles, and minimum and maximum values. There was no statistical significance by Kruskal-Wallis test.

**Supplemental Figure 1**


**Figure S2**

**Serum CXCL9, CXCL10, CXCL11, CXCL13 and IL-21 levels for patients with acute and chronic HBV infection.** A. Serum CXCL9, CXCL10, CXCL11, CXCL13, IL-21, ALT, HBV DNA and HBsAg levels were compared between the HBeAg-positive/anti-HBe-negative sAH patients (n=18) and the HBeAg-positive/anti-HBe-negative pAH patients (n=8) groups. \*  $p < 0.05$ , \*\*  $p < 0.001$ , \*\*\*  $p < 0.0001$  by Mann-Whitney non-parametric U test. B. Serum CXCL9, CXCL10, CXCL11, CXCL13, IL-21, ALT, HBV DNA and HBsAg levels were compared among the HBeAg-positive/anti-HBe-negative (n=18), HBeAg-positive/anti-HBe-positive (n=16), and HBeAg-negative/anti-HBe-positive (n=7) sAH groups. \*  $p < 0.05$ , \*\*  $p < 0.001$  by Kruskal-Wallis test. C. Serum CXCL9, CXCL10, CXCL11, and CXCL13 levels were compared between HBeAg-negative (n=3) and HBeAg-positive (n=5) CH patients at hepatic flare.




**Figure S3**


**Longitudinal and comparative analysis of serum chemokines/cytokines in patients with self-limited HBV infection.** The changes of 36 chemokines/cytokines, except for CXCL9, CXCL10, CXCL11, CXCL13 and IL-21, in Cases AH1, AH2, AH3 and AH4 are shown (A-D). Dotted lines in the panels indicate the average chemokine concentration in healthy volunteers. The shaded area depicts the time period of HBsAg-negative. The left vertical axes are for alanine aminotransferase (ALT), and the right vertical axes are for HBV DNA.

**Supplemental Figure 3A**


Supplemental Figure 3B



Supplemental Figure 3C



## Supplemental Figure 3D






Supplemental Figure 4B

Ch2

HBVDNA (logcopies/ml) —  
ALT (IU/L) ■



HBsAg (S/N)  
anti-HBs (mIU/mL)  
anti-HBc (%NH)

